In a groundbreaking development, brain implants are emerging as a potential game-changer in the treatment of various neurological and chronic conditions. Startups across the globe are engaging in clinical trials to explore the possibilities of this cutting-edge technology, which could significantly improve the lives of millions and create a market worth more than £15 billion by the 2030s.
One notable success story is that of Oran Knowlson, a British teenager with severe Lennox-Gastaut syndrome, a rare form of epilepsy. Oran became the first person worldwide to trial a new brain implant, resulting in an impressive 80% reduction in his daytime seizures. The device, called Picostim, sits under the skull and delivers constant electrical signals deep into the brain, aiming to block abnormal impulses that trigger seizures.
The potential applications of brain implants extend far beyond epilepsy. Companies like Inbrain Neuroelectronics in Barcelona are developing graphene-based implants to treat brain cancer, Parkinson’s disease, and speech problems caused by strokes. Graphene, a revolutionary material discovered at Manchester University, offers unique advantages due to its ultra-thin structure and biocompatibility.
Galvani Bioelectronics, a joint venture between GSK and Verily Life Sciences, is focusing on the peripheral nervous system. Their lead therapy aims to treat rheumatoid arthritis by stimulating the splenic nerve, with clinical trials underway in the UK, US, and Netherlands. The market for bioelectronics, which combines biological science and electrical engineering, is currently valued at £8.7 billion and is projected to surpass £15 billion by 2031.
When considering brain-focused neuromodulation and brain-computer interfaces, the total market could exceed $25 billion. As the race to develop life-changing brain implants intensifies, Europe and the UK are well-positioned to compete with the US. With a growing number of startups and academic collaborations, the region is poised to make significant strides in this transformative field. The ultimate goal is to bring these innovative therapies to the NHS and make them accessible to patients worldwide.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.